Published online before print December 2, 2002, doi: 10.1161/01.HYP.0000050929.96979.EC
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:93.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Endothelin-1 Contributes to the Frank-Starling Response in Hypertrophic Rat Hearts
From the Department of Pharmacology and Toxicology (J.P., I.Sz., P.K., H.R.) and the Department of Physiology (M.I., O.V.), Biocenter Oulu, University of Oulu, Oulu, Finland; the Heart Institute, Faculty of Medicine, University of Pécs (I.Sz.), Pécs, Hungary; and the First Department of Medicine, Semmelweis University, and Molecular Genetic Research Group of the Hungarian Academy of Science (R.d.C.), Budapest, Hungary.
Correspondence to Heikki Ruskoaho, MD, PhD, Department of Pharmacology and Toxicology, Faculty of Medicine, University of Oulu, PO Box 5000, FIN-90014, University of Oulu, Finland. E-mail heikki.ruskoaho{at}oulu.fi
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Endothelin-1 is involved in mechanical load–induced cardiac growth processes; it also has effects on contractility. The interaction of endothelin-1 and the Frank-Starling response is unknown. The present study aimed to characterize the role of endothelin-1 in the regulation of the Frank-Starling response, one of the major mechanisms regulating cardiac contractile force, in both normal and hypertrophied hearts. Nontransgenic rat hearts and hypertrophic hearts of hypertensive double transgenic rats harboring human angiotensinogen and renin genes were studied in a Langendorff isolated heart setup with a liquid-filled balloon inside the left ventricle used to measure contractile parameters. The rats were studied at compensated phase, before showing any signs of heart failure. Compensated hypertrophy in double transgenic rat hearts resulted in improved contractility at a given level of preload when compared with nontransgenic rat hearts. Hearts of both rat lines showed preserved Frank-Starling responses, that is, increased contractile function in response to increased end-diastolic pressure. The mixed endothelin A/B receptor antagonist bosentan attenuated the Frank-Starling response by 53% (P<0.01) in the double transgenic hearts but not in nontransgenic hearts. The diastolic parameters remained unaffected. The left ventricles of the double transgenic rat hearts showed an 82% higher level of endothelin type A receptor mRNA and a 25% higher level of immunoreactive endothelin-1 compared with nontransgenic rat hearts. The type 1 angiotensin II receptor antagonist CV-11974 had no significant effect on contractile function in response to load in either strain. These results show that endogenous endothelin-1 contributes to the Frank-Starling response in hypertrophied rat hearts by affecting systolic performance.
Key Words: angiotensin II • endothelin • hypertrophy • rats, transgenic • stress, mechanical
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The three basic mechanisms regulating contractile force in vivo are the Frank-Starling mechanism, that is, increased contractile force in response to elevated end-diastolic volume,1 the force-frequency relation, and the sympathetic nervous system. In hypertrophied hearts, the force-frequency relation and the ß-adrenoceptor systems are impaired,2,3 whereas previous studies have suggested that the Frank-Starling mechanism is maintained in both hypertrophied4 and failing hearts.5
The stretch of cardiac muscle generates a biphasic force response. The immediately occurring rapid phase of the Frank-Starling mechanism is thought to be mediated by length-dependent activation of contractile element. This is mediated, at least partially, by increased Ca2+ affinity of the Ca2+-binding part of the contractile element, troponin C.6 During the following minutes, the slow phase develops, accounting for 
20% of the total contractile response to load in physiological temperatures.7 Previously, it has been shown that basal release of nitric oxide contributes to the Frank-Starling response by decreasing the diastolic stiffness,8 but otherwise little is known concerning the regulation of this response by paracrine/autocrine mediators.
In the long term, mechanical overload of the heart leads to compensatory left ventricular hypertrophy (LVH) and eventually to heart failure. Myocyte stretch has been suggested to induce the release of angiotensin II (Ang II) and endothelin-1 (ET-1), which then both contribute to the hypertrophic growth response.9,10 Elevated plasma levels of ET-1 have been demonstrated in chronic heart failure (CHF) in humans11 and experimental animal models,12 and studies with ET-1 receptor antagonist treatment in experimental models of CHF have shown improvement in cardiac function and survival.13–15 However, the usefulness of these drugs in chronic CHF in humans has not yet been confirmed by clinical trials. Surprisingly, a report from the REACH-1 trial suggested that initiation of high-dose treatment with the endothelin A/B (ETA/B) receptor antagonist bosentan is accompanied by an increased number of events leading to worsening clinical status.16 This may reflect a role of ET-1 in the maintenance of cardiac contractile function in failing hearts, as suggested by a previous study with experimental CHF.12
ET-1 has a direct positive inotropic effect on the heart in vitro,17,18 whereas the effects of Ang II are more complex.19 ET-1 also increases the contractile efficacy in isolated rat hearts.20 However, it has not been established whether ET-1 contributes to the Frank-Starling response. To test this hypothesis, we studied the regulation of the Frank-Starling mechanism in isolated perfused hearts of both normotensive, nontransgenic (NTG) Sprague-Dawley rats and hypertensive double transgenic (dTG) rats harboring human renin and angiotensinogen genes21 by using the mixed ETA/B receptor antagonist bosentan. Furthermore, the angiotensin type 1 (AT1) receptor antagonist CV-11974 was used to study whether Ang II is involved in the regulation of the Frank-Starling response. The dTG rat model was chosen because both ET-1 and Ang II contribute to the end-organ damage in this rat strain.22
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals
Experiments were conducted in 7- to 8-week-old male dTG rats harboring both the human angiotensinogen and human renin genes21 (n=72) and in age-matched normotensive NTG rats (n=68). None of the dTG rats showed any clinical signs of heart failure, including ascites or pleural effusion. The dTG and NTG rat strains were obtained from Møllegaard Breeding Center Deutschland Gmbh (Schönwalde, Germany) and RCC Ltd (Itingen, Switzerland). The rats were kept in plastic cages with free access to tap water and normal rat chow. The Animal Use and Care Committee of the University of Oulu approved the experimental design.
Drugs
The following drugs were used: bosentan, CV-11974, GF-109203X, and zoniporide. Bosentan was generously supplied by Dr Martine Clozel, Hoffmann-La Roche Ltd (Basel, Switzerland) and Actelion Ltd (Basel, Switzerland), CV-11974 by Dr Hajime Toguchi, Takeda Chemical Industries Ltd (Osaka, Japan), and zoniporide by Dr Ross Tracey, Pfizer Inc (Groton, Conn). GF-109203X was purchased from Calbiochem.
Isolated Perfused Heart Preparation
The retrograde perfusion system and the Krebs-Henseleit bicarbonate buffer were similar, as previously described.23,24 Left ventricular contractility was assessed by measuring isovolumic left ventricular pressure with a fluid-filled balloon placed in the left ventricular chamber.24 For more detailed description of the preparation, please see the online data supplement at http://hyper.ahajournals.org.
Experimental Protocol and Analysis
The 50-minute stabilization period was followed by 10 minutes of pretreatment with the desired drug. Thereafter, the infusion was continued and the volume of the intraventricular balloon was increased in 10-µL steps. The control experiments were continued at a left ventricular end-diastolic pressure (LVEDP) of 3 mm Hg. Cardiac function was assessed within 1 minute of each volume increment, when a new steady state was reached. The whole assessment of the Frank-Starling response was completed within 15 minutes.
The concentrations of bosentan (1 µmol/L), CV-11974 (10 nmol/L), GF-109203X (90 nmol/L), and zoniporide (1 µmol/L) were chosen because these concentrations are known to effectively block ETA/B receptors17,25,26 and AT1 receptors,25,26 to suppress protein kinase C activity,24 and to inhibit Na+-H+ exchanger isoform 1 (NHE-1),27 respectively.
Maximal balloon volume (Vmax) was defined as the value at which peak developed pressure (DP) was reached, and a further increase led to a decrease of DP. Due to the different size of left ventricles of the dTG and NTG rats, comparison between dTG and NTG ventricular function was done at an LVEDP of 3 mm Hg and also at 50% of the Vmax.4 For analysis of mRNA and peptide levels, left ventricles of unstretched, vehicle-treated hearts were used.
Radioimmunoassay
The ET-1 radioimmunoassay was performed as previously described.28 Tissue ET-1 is expressed per milligram of wet weight.
Isolation and Analysis of Cytoplasmic RNA
RNA isolation and atrial natriuretic peptide (ANP), c-fos, and 18S RNA Northern blot analysis were performed as described.29
Real-Time Quantitative Reverse Transcription–Polymerase Chain Reaction
ETA receptor, ET-1, AT1 receptor, ACE, phospholamban, NHE-1, and Na+-Ca2+-exchanger (NCX) mRNA levels were measured by real-time quantitative reverse transcription–polymerase chain reaction analysis, using Taqman chemistry on an ABI Prism 7700 Sequence Detection System (Applied Biosystems) as described.30 For forward and reverse primers and probes for mRNA detection, please see the online data supplement at http://hyper.ahajournals.org.
Statistics
The results are expressed as mean±SEM. The Student t test was used for the comparison between 2 groups. The hemodynamic variables were analyzed with 1-way ANOVA followed by the Student-Newman-Keuls post hoc test. Repeated-measures ANOVA was used for multivariate analysis. Differences at the 95% level were considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cardiac Function in NTG and dTG Rat Lines
The dTG rat line is characterized by high blood pressure and remarkable LVH.21 The body weights of NTG and dTG rats were 219±4 and 204±3 g, respectively (P<0.001). The left ventricles of NTG and dTG rats weighed 618±10 and 891±17 mg, respectively, resulting in a left ventricle/body weight ratio of 2.83±0.03 and 4.37±0.06 mg/g (P<0.0001). In addition, the alterations in the cardiac gene expression were analyzed by measuring the expression levels of ANP, a hallmark of LVH, and c-fos, a proto-oncogene implicated in alteration of gene expression in response to mechanical stimulus. The ANP and c-fos mRNA levels were 9.2- and 1.6-fold higher in dTG than in NTG rat left ventricles, respectively (P<0.001 and P<0.05, Figure 1).
|
P<0.001.Adequate Frank-Starling responses were noted in both NTG and dTG hearts when the intraventricular balloon volume was increased. The dTG rat hearts showed augmented contractile function in comparison with NTG rat hearts at a given level of preload (LVEDP=3 mm Hg, Table). Also at corresponding operating points of the Frank-Starling curve, 50% of the Vmax, the contractile function was increased in dTG rat hearts (Table and Figure 2). Because of the geometrical changes in hypertrophied dTG hearts, the Vmax was 186±18 µL compared with 234±22 µL in NTG hearts (P=0.05).
|
|
Role of ET-1 and Ang II in the Frank-Starling Response
To determine the role of ET-1 and Ang II in regulation of the Frank-Starling response, bosentan (mixed ETA/B antagonist) and CV-11974 (AT1 receptor antagonist) were used in Langendorff-perfused NTG and dTG rat hearts during the increment of intraventricular balloon volume. In NTG rat hearts, the antagonists had no effect on the Frank-Starling response (n=8 and n=5, respectively, Figure 3). In contrast, the increase in DP and dP/dtmax was attenuated by 53% and 61% (P<0.01 for both parameters, n=8), respectively, in the presence of bosentan in dTG rat hearts (Figure 3). CV-11974 did not have a significant effect (n=7, Figure 3). Bosentan and CV-11974 did not influence the diastolic stiffness, as shown by a similar increase in LVEDP with increasing balloon volumes. Also, minimal negative derivatives of intraventricular pressure, dP/dtmin, were unaffected by the antagonists (Figure 4), suggesting that alterations seen in the Frank-Starling response are related to systolic rather than diastolic function. Bosentan or CV-11974 had no effect on contractile parameters in control-perfused hearts (LVEDP=3 mm Hg) (DP change: dTG, -3.7±3.8% and 0±2.7%; NTG, -1.6±2.0% and -3.1±2.8% during the 30-minute infusion with bosentan and CV-11974, respectively). The coronary flow rate of 5.8 mL/g per minute resulted in 30±1 and 54±2 mm Hg perfusion pressure in NTG and dTG rat hearts, respectively (P<0.001). The increased perfusion pressure in dTG rats probably is due to alterations in vascular morphology caused by hypertension.31 As also previously reported,25–27 these drugs did not have any effect on perfusion pressure under these experimental conditions (perfusion pressure change: dTG, -0±0.8% and -0.3±0.4 mm Hg; NTG, -0.3±0.1 and -0.9±0.5 mm Hg during the 30-minute infusion with bosentan and CV-11974, respectively), indicating that the observed changes in contractility cannot be attributed to alterations in coronary vascular tone.
|
|
PKC and NHE have been suggested to mediate the positive inotropic effect of exogenous ET-1 in cardiac myocytes.18 To assess the role of PKC and NHE-1 as downstream mediators of ET-1 signaling in the Frank-Starling response in dTG hearts, the effect of GF-109203X, a selective PKC inhibitor, and zoniporide, a potent and selective inhibitor of NHE-1, were tested. The dP/dtmax increased to 143±4% and 135±3% of baseline in vehicle-infused and GF-109203X–infused hearts, respectively (P=0.08). Moreover, during the stepwise increase in the intraventricular balloon volume, the increase in dP/dtmax was significantly attenuated in the presence of GF-109203X in comparison with vehicle infusion (P<0.05, Figure 5). In contrast, zoniporide had no effect on the Frank-Starling response, with dP/dtmax increasing to 148±4% (P=NS versus vehicle). The drugs had no effect on baseline (LVEDP=3 mm Hg) contractile force or the perfusion pressure. In NTG rats, the Frank-Starling response remained unaltered during the infusion with GF-109203X and zoniporide (data not shown).
|
0.05.
Characterization of the ET-1 System in NTG and dTG Rat Hearts
Because a significant contribution of ET-1 to the Frank-Starling response in dTG but not in NTG rat hearts was observed, we investigated the activity of the endothelin system in left ventricles of both strains. Immunoreactive ET-1 peptide levels were 25% higher in the left ventricles of control-perfused dTG than NTG hearts (P<0.05, Figure 6). Furthermore, the ETA receptor mRNA level was 82% higher in dTG left ventricles (P<0.05, Figure 6). There was no difference between NTG and dTG rat left ventricles in ET-1 mRNA levels. A 29% decrease in AT1 receptor mRNA was noted in dTG left ventricles (P<0.005, Figure 5). The ACE mRNA levels were similar in the left ventricles of both rat lines (data not shown). Further analysis to investigate possible mechanisms by which the ET-1 stimulation might influence contractility showed no differences between the rat lines in the NHE-1 (dTG, 0.71±0.15 versus NTG, 0.73±0.10 arbitrary units), or phospholamban (dTG, 1.00±0.05 versus NTG, 0.98±0.09 arbitrary units) mRNA levels. The NCX mRNA levels in dTG rat left ventricles were 28±8% higher than those in NTG rat left ventricles (dTG, 0.89±0.05 versus NTG, 0.69±0.02 arbitrary units, P<0.05).
|
Regulation of the Frank-Starling Response in SHR Hearts
To test whether involvement of ET-1 in the Frank-Starling response is limited to severe LVH as in dTG rats, the effect of bosentan and CV-11974 were tested in 8-week-old spontaneously hypertensive rat (SHR) hearts, and age-matched Wistar-Kyoto (WKY) control rats (left ventricle/body weight ratio of 2.90±0.16 and 2.60±0.07 mg/g, respectively, P<0.05). Our results showed that bosentan and CV-11974 had no effect on the Frank-Starling response in SHR hearts (maximal DP compared with the level at LVEDP=3 mm Hg: 153±8, 163±8% and 164±7%, vehicle, bosentan, and CV-11974 treated hearts, respectively, P=NS). In contrast to the dTG rat hearts, mRNA levels of ETA receptor were similar in SHR and WKY rat hearts (1.50±0.40 versus 1.63±0.37 arbitrary units, SHR versus WKY, P=NS).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The key finding of the present study is that endogenous ET-1 contributes to the Frank-Starling response in dTG rat hearts with compensated LVH but not in normal NTG rat hearts. The observation that ETA/B receptor antagonist impaired the Frank-Starling response in dTG rat hearts raises the question of whether this was due to the alteration of diastolic or systolic function. Basal release of ET-1 is known to delay left ventricular relaxation in normal guinea pig hearts,32 and the mechanism behind augmentation of Frank-Starling response by basal release of NO appears to be mediated by improved diastolic distensibility.8 As shown in Figure 4, similar increase in LVEDP was observed when bosentan or vehicle was infused in dTG rat hearts, suggesting that the diastolic stiffness was not affected by endogenous ET-1. In addition, there was no change in maximal rate of isovolumic relaxation, dP/dtmin, in response to bosentan. Thus, the inhibition of the Frank-Starling response in dTG rat hearts by ET-1 receptor blockade appears to be mediated by alteration of the systolic function.
In contrast with the results obtained with bosentan, the AT1 receptor blocker CV-11974 did not have any significant effect on the Frank-Starling response in dTG rat hearts, even though increased Ang II release has been suggested to induce ET-1 action in response to myocyte stretch in the heart.7,22 The renin-angiotensin system components are found also in normal rat hearts, and they are induced during cardiac hypertrophy and failure.9 A role for locally generated Ang II in the Frank-Starling mechanisms in vivo cannot be excluded, since it is possible that local Ang II production would need blood-derived renin to be completely active,33 but in this model Ang II does not appear to be as significant a regulator of contractile function as ET-1.
Previous studies suggest that stretch-induced release of Ang II and ET-1 stimulates the NHE and thereby possibly activates the NCX in its reverse mode (Ca2+ in–Na+ out). This has been suggested to be the mechanism for the slow phase of the Frank-Starling response in a cat papillary muscle preparation.7 In the whole-organ model used in our study, it is difficult to dissect between the slow and rapid phases, and therefore the peak contractile values are a result of combination of both slow and rapid phases of the Frank-Starling response. Our results are at variance with those of Pérez et al,7 since the Frank-Starling response was not affected by ETA/B or AT1 antagonism or inhibition of NHE-1 in normal rat hearts.
Previously, PKC has been implicated in ET-1–induced responses in cardiomyocytes.18,34 The present results suggest that PKC is involved in the regulation of the Frank-Starling response in dTG rat hearts. Since the effect of GF-109203X was less prominent than that of bosentan, apparently other signaling mechanisms can contribute to this response. Endogenous ET-1 may also affect the properties of the more downstream elements of the contractile machinery, such as the Ca2+ affinity of the troponin C or the actomyosin cycling rate in hypertrophied hearts.35 Furthermore, contribution of the endogenous ET-1 system to the Frank-Starling mechanism in the hypertrophied dTG rat hearts may be related to the ET-1–mediated improvement of the contractile efficacy.20
Based on our present results and those of previous studies, the Frank-Starling mechanism is preserved in hypertrophied and even in failing hearts.5 In contrast, the force-frequency relation and the ß-adrenoceptor system are impaired in various models of LVH and CHF.2,3,36 Therefore, in these pathological conditions, the adaptation of the heart to varying levels of load is more dependent on the Frank-Starling response. Our findings imply that endogenous ET-1 plays a significant role in the maintenance of cardiac function during acute increases in hemodynamic load in severely hypertrophied hearts with an upregulated ET-1 system by contributing to the Frank-Starling response.
Perspectives
ET-1 contributes to the pathophysiology of cardiac hypertrophy and failure.10,37,38 Treatment with endothelin antagonists appears to be an attractive alternative to improve the poor prognosis of these patients by decreasing peripheral resistance39 and interrupting the direct growth-promoting effect of ET-1.13 However, previous reports showed that initiation of high-dose bosentan treatment worsened the clinical status in patients with CHF.16 Our results demonstrate that ET-1 contributes significantly to the Frank-Starling response in severely hypertrophied dTG rat hearts, providing a possible mechanism for the adverse effects observed in patients.16 Together with the previous findings, our results suggest that special care should be taken with endothelin receptor antagonist treatment in severe LVH because of the effects on the Frank-Starling response.12,16 In contrast to ETA/B antagonist bosentan, the AT1 receptor antagonist CV-11974 does not appear to affect the Frank-Starling mechanism, which agrees with the findings that pharmacological blockade of the renin-angiotensin system is well tolerated and improves survival in patients with CHF.34
|
Acknowledgments |
|---|
This study was supported by grants from the Academy of Finland, the Sigrid Juselius Foundation, the Finnish Foundation for Cardiovascular Research, the Aarne Koskelo Foundation, the Research and Science Foundation of Farmos, the Hungarian Research Foundation (OTKA: F035213), and the Ministry of Health of Hungary (ETT: 304/2000). We thank Drs Ursula Ganten and Dominik N. Müller for providing us the dTG rats and Marja Arbelius, Tuula Lumijärvi, Ulla Weckström, Sirpa Rutanen, and Kati Viitala for technical assistance.
Received April 9, 2002; first decision May 2, 2002; accepted October 29, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Sarnoff SJ, Berglund E. Ventricular function. I. Starling’s law of the heart studied by means of simultaneous right and left ventricular function curves in the dog. Circulation. 1954; 9: 706–718.[Medline] [Order article via Infotrieve]
2. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992; 85: 1743–1750.
3. Dzimiri N. Regulation of beta-adrenoceptor signaling in cardiac function and disease. Pharmacol Rev. 1999; 51: 465–501.
4. Strömer H, Cittadini A, Szymanska G, Apstein CS, Morgan JP. Validation of different methods to compare isovolumic cardiac function in isolated hearts of varying sizes. Am J Physiol. 1997; 272: H501–H510.[Medline] [Order article via Infotrieve]
5. Holubarsch C, Ruf T, Goldstein DJ, Ashton RC, Nickl W, Pieske B, Pioch K, Ludemann J, Wiesner S, Hasenfuss G, Posival H, Just H, Burkhoff D. Existence of the Frank-Starling mechanism in the failing human heart: investigations on the organ, tissue, and sarcomere levels. Circulation. 1996; 94: 683–689.
6. Kentish JC, Wrzosek A. Changes in force and cytosolic Ca2+ concentration after length changes in isolated rat ventricular trabeculae. J Physiol (Lond). 1998; 506: 431–444.
7. Pérez NG, de Hurtado MC, Cingolani HE. Reverse mode of the Na+-Ca2+ exchange after myocardial stretch: underlying mechanism of the slow force response. Circ Res. 2001; 88: 376–382.
8. Prendergast BD, Sagach VF, Shah AM. Basal release of nitric oxide augments the Frank-Starling response in the isolated heart. Circulation. 1997; 96: 1320–1329.
9. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res. 1999; 85: 643–650.
10. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001; 41: 851–876.[CrossRef][Medline] [Order article via Infotrieve]
11. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC Jr. Endothelin in human congestive heart failure. Circulation. 1994; 89: 1580–1586.
12. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart. Circulation. 1996; 93: 1214–1222.
13. Ito H, Hiroe M, Hirata Y, Fujisaki H, Adachi S, Akimoto H, Ohta Y, Marumo F. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation. 1994; 89: 2198–2203.
14. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996; 384: 353–355.[CrossRef][Medline] [Order article via Infotrieve]
15. Mishima T, Tanimura M, Suzuki G, Todor A, Sharov VG, Goldstein S, Sabbah HN. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol. 2000; 35: 222–229.
16. Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Eur J Heart Fail. 1999; 1: 197–200.[CrossRef][Medline] [Order article via Infotrieve]
17. Kinnunen P, Szokodi I, Nicholls MG, Ruskoaho H. Impact of NO on ET-1- and AM-induced inotropic responses: potentiation by combined administration. Am J Physiol Regul Integr Comp Physiol. 2000; 279: R569–R575.
18. Krämer BK, Smith TW, Kelly RA. Endothelin and increased contractility in adult rat ventricular myocytes: role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na+-H+ exchanger. Circ Res. 1991; 68: 269–279.
19. Li P, Sonnenblick EH, Anversa P, Capasso JM. Length-dependent modulation of ANG II inotropism in rat myocardium: effects of myocardial infarction. Am J Physiol. 1994; 266: H779–H786.[Medline] [Order article via Infotrieve]
20. Takeuchi Y, Kihara Y, Inagaki K, Yoneda T, Sasayama S. Endothelin-1 has a unique oxygen-saving effect by increasing contractile efficiency in the isolated rat heart. Circulation. 2001; 103: 1557–1563.
21. Bohlender J, Fukamizu A, Lippoldt A, Nomura T, Dietz R, Menard J, Murakami K, Luft FC, Ganten D. High human renin hypertension in transgenic rats. Hypertension. 1997; 29: 428–434.
22. Bohlender J, Gerbaulet S, Krämer J, Gross M, Kirchengast M, Dietz R. Synergistic effects of AT1 and ETA receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension. 2000; 35: 992–997.
23. Szokodi I, Kinnunen P, Tavi P, Weckström M, Tóth M, Ruskoaho H. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation. 1998; 97: 1062–1070.
24. Szokodi I, Tavi P, Földes G, Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen P, Piuhola J, Rysä J, Tóth M, Ruskoaho H. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002; 91: 434–440.
25. Magga J, Vuolteenaho O, Marttila M, Ruskoaho H. Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ETA/ETB and AT1 receptor antagonists in vivo and in vitro. Circulation. 1997; 96: 3053–3062.
26. Hautala N, Tenhunen O, Szokodi I, Ruskoaho H. Direct left ventricular wall stretch activates GATA4 binding in perfused rat heart: involvement of autocrine/paracrine pathways. Pflugers Arch. 2002; 443: 362–369.[CrossRef][Medline] [Order article via Infotrieve]
27. Knight DR, Smith AH, Flynn DM, MacAndrew JT, Ellery SS, Kong JX, Marala RB, Wester RT, Guzman-Perez A, Hill RJ, Magee WP, Tracey WR. A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo. J Pharmacol Exp Ther. 2001; 297: 254–259.
28. Leskinen H, Ruskoaho H, Huttunen P, Leppäluoto J, Vuolteenaho O. Hemorrhage effects on plasma ANP, NH2-terminal pro-ANP, and pressor hormones in anesthetized and conscious rats. Am J Physiol. 1994; 266: R1933–R1943.[Medline] [Order article via Infotrieve]
29. Piuhola J, Hammes A, Schuh K, Neyses L, Vuolteenaho O, Ruskoaho H. Overexpression of sarcolemmal calcium pump attenuates induction of cardiac gene expression in response to ET-1. Am J Physiol Regul Integr Comp Physiol. 2001; 281: R699–R705.
30. Majalahti-Palviainen T, Hirvinen M, Tervonen V, Ilves M, Ruskoaho H, Vuolteenaho O. Gene structure of a new cardiac peptide hormone: a model for heart-specific gene expression. Endocrinology. 2000; 141: 731–740.
31. Feigl EO. Coronary physiology. Physiol Rev. 1983; 63: 1–205.
32. Prendergast BD, Anning PB, Lewis MJ, Shah AM. Regulation of left ventricular relaxation in the isolated guinea-pig heart by endogenous endothelin. Cardiovasc Res. 1997; 33: 131–138.
33. Müller DN, Fischli W, Clozel JP, Hilgers KF, Bohlender J, Menard J, Busjahn A, Ganten D, Luft FC. Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res. 1998; 82: 13–20.
34. Tavi P, Laine M, Weckström M, Ruskoaho H. Cardiac mechanotransduction: from sensing to disease and treatment. Trends Pharmacol Sci. 2001; 22: 254–260.[CrossRef][Medline] [Order article via Infotrieve]
35. Endoh M. Regulation of myocardial contractility by a downstream mechanism. Circ Res. 1998; 83: 230–232.
36. Bartel S, Hoch B, Vetter D, Krause EG. Expression of human angiotensinogen-renin in rat: effects on transcription and heart function. Hypertension. 2002; 39: 219–223.
37. Ry SD, Andreassi MG, Clerico A, Biagini A, Giannessi D. Endothelin-1, endothelin-1 receptors and cardiac natriuretic peptides in failing human heart. Life Sci. 2001; 68: 2715–2730.[CrossRef][Medline] [Order article via Infotrieve]
38. Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, Hirth G, Loffler BM, Muller M, Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993; 365: 759–761.[CrossRef][Medline] [Order article via Infotrieve]
39. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994; 344: 852–854.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  L. M. Salo, E. Nalivaiko, C. R. Anderson, and R. M. McAllen Control of cardiac rate, contractility, and atrioventricular conduction by medullary raphe neurons in anesthetized rats Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H318 - H324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J Ellmers, N. J A Scott, J. Piuhola, N. Maeda, O. Smithies, C. M Frampton, A M. Richards, and V. A Cameron Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis J. Mol. Endocrinol., February 1, 2007; 38(2): 245 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pikkarainen, H. Tokola, R. Kerkela, M. Ilves, M. Makinen, H.-D. Orzechowski, M. Paul, O. Vuolteenaho, and H. Ruskoaho Inverse regulation of preproendothelin-1 and endothelin-converting enzyme-1beta genes in cardiac cells by mechanical load Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2006; 290(6): R1639 - R1645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-F. Chen and Z. Sun Effects of chronic cold exposure on the endothelin system J Appl Physiol, May 1, 2006; 100(5): 1719 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. del Villar, C. J. G. Alonso, C. A. Feldstein, L. A. Juncos, and J. C. Romero Role of Endothelin in the Pathogenesis of Hypertension Mayo Clin. Proc., January 1, 2005; 80(1): 84 - 96. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Szokodi, J. Piuhola, and H. Ruskoaho Endothelin Receptor Blockade and Exacerbation of Heart Failure Circulation, June 10, 2003; 107 (22): e211 - e211. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||